Developing a new treatment for pulmonary hypertension
Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension
This study is testing a new treatment for pulmonary arterial hypertension (PAH) that uses a special antibody to block a protein linked to heart and lung problems, with the hope of helping patients feel better and live longer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aqualung Therapeutics Corp. NIH-funded |
| Lab location | 1 site (Juno Beach, UNITED STATES) |
| Project ID | NIH-10931660 on NIH RePORTER |
What this research studies
This research focuses on a novel therapy targeting pulmonary arterial hypertension (PAH), a serious condition that affects the lungs and heart. The approach involves a humanized monoclonal antibody designed to neutralize a specific protein called eNAMPT, which is linked to inflammation and worsening heart function in PAH patients. By blocking this protein, the research aims to improve right ventricular function and overall survival in individuals suffering from this disease. The study will utilize preclinical models to evaluate the effectiveness and safety of this new treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with pulmonary arterial hypertension who are experiencing right ventricular dysfunction.
Not a fit: Patients with pulmonary hypertension caused by factors unrelated to eNAMPT or those with other severe comorbidities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly improves outcomes for patients with pulmonary hypertension.
How similar studies have performed: Previous research has indicated that targeting inflammatory pathways in pulmonary hypertension can be effective, suggesting potential success for this novel approach.
Where this research is happening
Juno Beach, UNITED STATES
- Aqualung Therapeutics Corp. — Juno Beach, United States (Active)
Researchers
- Principal investigator: Garcia, Joe G. N. — Aqualung Therapeutics Corp.
- Study coordinator: Garcia, Joe G. N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.